sembra che qualcosa si stia muovendo. L'antitrust sta esaminando
l'accusa che le linee guida della IDSA siano state formulate senza un
attenta analisi.
In particolare a pagina 143:
AG Blumenthal‟s findings clearly demonstrate that “[t]he IDSA‟s Lyme
guideline process lacked important procedural safeguards.”217
The facts demonstrate
that the IDSA‟s guideline development process was not fair, open, or unbiased and
that the IDSA panel improperly influenced the guideline process by refusing to
meaningfully consider information regarding the existence of Lyme disease,
excluding scientists and physicians with divergent viewpoints, failing to conduct a
conflicts of interest review on the panelists, and failing to follow its own procedures
for appointing panel members.21
ed a pagina 144:
Because of this abuse in the guideline development process, the Guidelines deny
the existence of chronic Lyme disease and condemn the use of long-term
antibiotics,220
which limits consumers‟ diagnosis and treatment options and causes
economic harm to physicians who treat chronic Lyme patients.
L'accusa è di NEGARE L'ESISTENZA DELLA LYME CRONICA.
Un passo avanti. Speriamo che venga a galla la verità.
In allegato il PDF.